Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of MGd in non-small-cell lung cancer
(NSCLC) when given alone, and to evaluate the difference between two dosing regimens.